NRC expected to issue Mo-99 facility license for Shine in 2021

May 13, 2020, 9:10PMNuclear News

Shine Medical Technologies, which is building a medical isotope production facility in Janesville, Wis., said on May 11 that it expects to have an operating license issued by the Nuclear Regulatory Commission by October 2021. Shine’s application seeking approval to operate the facility, which will produce isotopes including molybdenum-99, was accepted and docketed by the NRC last October. Mo-99, the precursor to technetium-99m, is used in more than 40 million medical patient procedures every year.

To continue reading, log in or create a free account!

Related Articles

Aalo Atomics discusses the road ahead

March 12, 2026, 1:13PMNuclear News

Yasir Arafat, president and chief technology officer of Aalo Atomics, participated in the first day of sessions at the Nuclear Regulatory Commission’s annual Regulatory Information...

ANSTO-designed target increases Mo-99 yield

February 25, 2026, 1:00PMNuclear News

The Australian Nuclear Science and Technology Organization (ANSTO) announced that it has made progress on a more cost-effective way to produce the medical radioisotope molybdenum-99, with less...